Boston Heart Lab, a Framingham, MA-based provider of cardiovascular care management products and services, has raised $10 million in an equity and rights financing, according to an SEC filing. Company CEO Susan Hertzberg was not available for comment at her office today. The company’s website lists two members of the investment team at Boston-based Bain Capital Ventures—Jeff Crisan and Alice Limkakeng—as directors of the company. Peter Parker, the former CEO of Cambridge, MA-based Cequent Pharmaceuticals (now part of Marina Biotech of Bothell, WA), is listed as Boston Heart Lab’s chairman. Boston Heat Lab says it provides a proprietary lab tests to measure patients’ cholesterol as well as programs to track the health of people with cardiovascular disease.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
